Powered by

Merck to lay off 500 workers around the U.S. in continued shift to innovative meds

Oct 18, 2019 - FiercePharma

Merck has struggled with certain diabetes and cardiovascular drugs, but its cancer business⁠—including star checkpoint inhibitor Keytruda⁠—is booming. Now, the company is chopping 500 jobs nationwide as part of a continued shift to focus more on innovative drugs. The company is cuttingjobsin “select sales and headquarters commercial teams" effective Jan. 3.

Merck, like many of its Big Pharma peers,is working to focus more on innovative drugs. But as part of that ongoing shift, th...